StemCells, Inc. (NASDAQ: STEM) is currently engaged in clinical development of its HuCNS-SC platform technology (purified human neural stem cells) as a potential treatment for chronic spinal cord injury (SCI), according to the company’s website (see here: www.StemCellsInc.com). SNNLive spoke with Ian Massey, President and CEO of StemCells, Inc. at the Source Capital 2016 Disruptive Growth & Healthcare Conference in New York City, NY.
In this video interview, Mr. Massey and our host discuss the following topics:
- Overview of StemCells, Inc.
- Where the science was developed
- Discusses spinal cord injury
- Clinical development
- Size of the spinal cord injury market
- Mr. Massey’s background
- Milestones and goals for 2016
For more information about StemCells, Inc., go to: www.StemCellsInc.com
The interview may contain forward looking statements about StemCells, Inc. See StemCells' periodic filings with the Securities and Exchange Commission for more complete information.
© 2017 Stock News Now
Supported by Superior Web Solutions